Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer
- 29 July 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 385 (5), 395-405
- https://doi.org/10.1056/nejmoa2104162
Abstract
For postmenopausal women with hormone-receptor–positive breast cancer, the most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear.Keywords
Funding Information
- AstraZeneca
- ABCSG
This publication has 41 references indexed in Scilit:
- Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trialThe Lancet, 2015
- Breast cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III TrialJournal of Clinical Oncology, 2013
- Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patientsActa Oncologica, 2012
- Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast CancerJournal of Clinical Oncology, 2012
- Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study GroupJournal of Clinical Oncology, 2012
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerThe New England Journal of Medicine, 2009
- Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 TrialJournal of Clinical Oncology, 2008
- Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6aJNCI Journal of the National Cancer Institute, 2007
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerThe New England Journal of Medicine, 2003